ECSP034796A - DERIVADOS DIHIDRO-BENZO[b][1,4]DIAZEPIN-2-ONA ANTAGONISTAS I MGLUR2 - Google Patents

DERIVADOS DIHIDRO-BENZO[b][1,4]DIAZEPIN-2-ONA ANTAGONISTAS I MGLUR2

Info

Publication number
ECSP034796A
ECSP034796A EC2003004796A ECSP034796A ECSP034796A EC SP034796 A ECSP034796 A EC SP034796A EC 2003004796 A EC2003004796 A EC 2003004796A EC SP034796 A ECSP034796 A EC SP034796A EC SP034796 A ECSP034796 A EC SP034796A
Authority
EC
Ecuador
Prior art keywords
diazepin
dihidro
mglur2
ona
antagonists
Prior art date
Application number
EC2003004796A
Other languages
English (en)
Spanish (es)
Inventor
Jurgen Wichmann
Vincent Mutel
Geo Adam
Thomas Johannes Woltering
Erwin Goetschi
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP034796A publication Critical patent/ECSP034796A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EC2003004796A 2001-04-12 2003-10-08 DERIVADOS DIHIDRO-BENZO[b][1,4]DIAZEPIN-2-ONA ANTAGONISTAS I MGLUR2 ECSP034796A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01109126 2001-04-12

Publications (1)

Publication Number Publication Date
ECSP034796A true ECSP034796A (es) 2003-12-01

Family

ID=8177127

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004796A ECSP034796A (es) 2001-04-12 2003-10-08 DERIVADOS DIHIDRO-BENZO[b][1,4]DIAZEPIN-2-ONA ANTAGONISTAS I MGLUR2

Country Status (37)

Country Link
US (1) US6548495B2 (enExample)
EP (1) EP1379522B1 (enExample)
JP (1) JP4043953B2 (enExample)
KR (1) KR100566178B1 (enExample)
CN (1) CN1268626C (enExample)
AR (1) AR035456A1 (enExample)
AT (1) ATE287883T1 (enExample)
AU (1) AU2002310912B2 (enExample)
BG (1) BG108253A (enExample)
BR (1) BR0208887A (enExample)
CA (1) CA2441771C (enExample)
CZ (1) CZ20033002A3 (enExample)
DE (1) DE60202761T2 (enExample)
DK (1) DK1379522T3 (enExample)
EC (1) ECSP034796A (enExample)
ES (1) ES2235044T3 (enExample)
GT (1) GT200200072A (enExample)
HR (1) HRP20030791B1 (enExample)
HU (1) HUP0400991A3 (enExample)
IL (2) IL158021A0 (enExample)
JO (1) JO2273B1 (enExample)
MA (1) MA27011A1 (enExample)
MX (1) MXPA03009317A (enExample)
MY (1) MY130369A (enExample)
NO (1) NO325300B1 (enExample)
NZ (1) NZ528345A (enExample)
PA (1) PA8543201A1 (enExample)
PE (1) PE20021072A1 (enExample)
PL (1) PL367086A1 (enExample)
PT (1) PT1379522E (enExample)
RU (1) RU2270197C2 (enExample)
SI (1) SI1379522T1 (enExample)
SK (1) SK13692003A3 (enExample)
UY (1) UY27259A1 (enExample)
WO (1) WO2002083665A1 (enExample)
YU (1) YU79103A (enExample)
ZA (1) ZA200307242B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU27902A (sh) 1999-10-15 2004-11-25 F. Hoffmann-La Roche Ag. Derivati benzodiazepina
CN1856312A (zh) * 2003-07-25 2006-11-01 弗·哈夫曼-拉罗切有限公司 治疗急性和/或慢性神经系统疾病的mGluR2拮抗剂和AChE抑制剂的组合产品
EP1812392B1 (en) 2004-11-05 2008-07-09 F.Hoffmann-La Roche Ag Process for preparation of isonicotinic acid derivatives
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
WO2008128889A1 (en) * 2007-04-19 2008-10-30 F. Hoffmann-La Roche Ag Dihydro-benzo[b][1,4]diazepin-2-one sulfonamide derivatives
US8722894B2 (en) * 2007-09-14 2014-05-13 Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones
NZ584152A (en) 2007-09-14 2011-11-25 Ortho Mcneil Janssen Pharm 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
SI2203439T1 (sl) 2007-09-14 2011-05-31 Ortho Mcneil Janssen Pharm 1',3'-disubstituirani 4-fenil-3,4,5,6-tetrahidro-2H-1'H-(1,4')bipiridinil-2'-oni
RU2492170C9 (ru) 2007-11-14 2013-12-27 Орто-Макнейл-Янссен Фармасьютикалз, Инк. Имидазо[1,2-а]пиридиновые производные и их применение в качестве положительных аллостерических модуляторов рецепторов mglur2
AU2009289784B2 (en) 2008-09-02 2012-03-22 Addex Pharma S.A. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
US8697689B2 (en) 2008-10-16 2014-04-15 Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
WO2010060589A1 (en) 2008-11-28 2010-06-03 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
BRPI1010831A2 (pt) 2009-05-12 2016-04-05 Addex Pharmaceuticals Sa derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN102439008B (zh) 2009-05-12 2015-04-29 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
PT2649069E (pt) 2010-11-08 2015-11-20 Janssen Pharmaceuticals Inc Derivados de 1,2,4-triazolo[4,3-a]piridina e sua utilização como moduladores alostéricos positivos de recetores mglur2
JP5852665B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド 1,2,4−トリアゾロ[4,3−a]ピリジン誘導体およびmGluR2受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
WO2012062759A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
EP2602248A1 (en) 2011-12-05 2013-06-12 University Of Leicester Novel pyrrole compounds
MX2015004604A (es) 2012-10-23 2015-10-08 Hoffmann La Roche Antagonistas de los receptores metabotropicos de glutamato 2/3 (mglu2/3) para el tratamiento de los trastornos autistas.
TWI622592B (zh) * 2013-02-28 2018-05-01 衛材R&D企管股份有限公司 四氫咪唑並[1,5-d][1,4]氧氮雜卓衍生物
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
AU2015208233B2 (en) 2014-01-21 2019-08-29 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
ES2860298T3 (es) 2014-01-21 2021-10-04 Janssen Pharmaceutica Nv Combinaciones que comprenden moduladores alostéricos positivos del receptor glutamatérgico metabotrópico de subtipo 2 y su uso
RU2016144702A (ru) 2014-04-23 2018-05-24 Ф. Хоффманн-Ля Рош Аг Антагонисты mglu2/3 для лечения интеллектуальной недостаточности
CA2950952C (en) 2014-06-10 2023-01-10 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU953819A1 (ru) * 1980-08-25 1991-09-23 Физико-химический институт АН УССР 1-(Гидразинокарбонил)алкил-1,2-дигидро-3Н-1,4-бенздиазепин-2-оны, обладающие транквилизирующими и противосудорожными свойствами
JP2003506440A (ja) * 1999-08-05 2003-02-18 プレサイエント ニューロファーマ インコーポレイテッド 中枢神経系に関連する疾患の処置のための1,4−ジアゼピン誘導体
PT1224174E (pt) * 1999-10-15 2004-01-30 Hoffmann La Roche Derivados de benzodiazepina como antagonistas do receptor metabotropico do glutamato
YU27902A (sh) * 1999-10-15 2004-11-25 F. Hoffmann-La Roche Ag. Derivati benzodiazepina

Also Published As

Publication number Publication date
EP1379522A1 (en) 2004-01-14
NO325300B1 (no) 2008-03-25
BG108253A (bg) 2005-03-31
GT200200072A (es) 2003-06-19
EP1379522B1 (en) 2005-01-26
MXPA03009317A (es) 2004-02-12
CA2441771A1 (en) 2002-10-24
KR100566178B1 (ko) 2006-03-29
JP4043953B2 (ja) 2008-02-06
CN1522252A (zh) 2004-08-18
UY27259A1 (es) 2002-10-31
SI1379522T1 (en) 2005-04-30
HUP0400991A2 (hu) 2004-08-30
ATE287883T1 (de) 2005-02-15
NZ528345A (en) 2005-04-29
HRP20030791A2 (en) 2005-06-30
DE60202761D1 (de) 2005-03-03
PL367086A1 (en) 2005-02-21
WO2002083665A1 (en) 2002-10-24
NO20034496L (no) 2003-10-08
CZ20033002A3 (cs) 2004-03-17
DE60202761T2 (de) 2006-01-12
MY130369A (en) 2007-06-29
PT1379522E (pt) 2005-05-31
IL158021A0 (en) 2004-03-28
AU2002310912B2 (en) 2005-06-16
HRP20030791B1 (en) 2006-06-30
AR035456A1 (es) 2004-05-26
ES2235044T3 (es) 2005-07-01
US6548495B2 (en) 2003-04-15
NO20034496D0 (no) 2003-10-08
RU2003130648A (ru) 2005-04-10
JP2004525965A (ja) 2004-08-26
JO2273B1 (en) 2005-04-07
ZA200307242B (en) 2004-12-16
PE20021072A1 (es) 2002-12-07
SK13692003A3 (sk) 2004-05-04
BR0208887A (pt) 2004-06-29
YU79103A (sh) 2006-05-25
CN1268626C (zh) 2006-08-09
DK1379522T3 (da) 2005-05-30
KR20030088502A (ko) 2003-11-19
IL158021A (en) 2010-04-15
HK1068339A1 (en) 2005-04-29
RU2270197C2 (ru) 2006-02-20
US20020198197A1 (en) 2002-12-26
MA27011A1 (fr) 2004-12-20
HUP0400991A3 (en) 2009-06-29
PA8543201A1 (es) 2002-10-31
CA2441771C (en) 2008-12-30

Similar Documents

Publication Publication Date Title
UY27258A1 (es) Derivados de dihidro-benzo b 1, 4 diazepin-2-ona como antagonistas ii mglur2
ECSP034796A (es) DERIVADOS DIHIDRO-BENZO[b][1,4]DIAZEPIN-2-ONA ANTAGONISTAS I MGLUR2
UY27654A1 (es) Derivados de dihidrobenzodiazepin-ona iii
ECSP066391A (es) [1,8] naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia
PA8462401A1 (es) Derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos
CR6726A (es) Compuestos azapoliciclicos condensados con arilo
SV2002000478A (es) Derivados de tiofeno utiles como anticancerosos ref. pc10795aagl/bb
UY28150A1 (es) Agentes terapeuticos
AR028824A1 (es) Compuestos antagonistas npy-5 y su uso en la manufactura de medicamentos.
HN1999000080A (es) Derivados de isotiazol utiles como agentes anticancerosos.
GT199900146A (es) Derivados de 4,4-biarilpiperidina.
GT200100160A (es) Derivados 4-fenil-piridina.
UY28314A1 (es) Preparacion y uso de derivados de alquilarilo para el tratamiento de la obesidad
SV1999000251A (es) Derivados de 3,3-biarilpiperidina y 2,2-biarilmorfolina ref. pcl0085/82805/bb
UY28144A1 (es) Agentes terapéuticos
UY28859A1 (es) Antagonistas de cgrp seleccionados, procedimiento para su preparación así como su uso como medicamento
PA8468501A1 (es) Compuestos heterociclicos como inhibidores de enzimas rotamasas
AR021843A1 (es) Derivados de propanolamina sustituidos con heterociclos, procedimiento para su preparacion, y su utilizacion.
PA8487701A1 (es) Derivados de 3,3-biarilpiperidina y 2,2-biarilmorfolina
UY28377A1 (es) Agentes terapeuticos
AR029428A1 (es) DERIVADOS DE FENIL--PIPERIDINA, TETRAHIDROPIRIDINA,-PIPERAZINA,-AZEPAN,-TETRAHIDRO-1H-AZEPINA Y DIAZEPAN SUSTITUIDOS, UNA COMPOSICIoN FARMACEUTICA Y EL USO DE LOS MISMOS PARA LA MANUFACTURA DE UNA PREPARACION FARMACEUTICA
CR10255A (es) "nuevas composiciones terapéuticas para el tratamiento o la prevención de trastornos psicóticos"
ES2086579T3 (es) Antagonista de leucotrieno b4.
UY27998A1 (es) Piperazinas sustituidas sustituidas heterocíclicas para el tratamiento de la esquizofrenia
ECSP066605A (es) Derivados oxazol de tetraciclina